Copper(II)-Catalyzed Dehydrogenative Cross-Coupling between Two Azoles

Xurong Qin, Boya Feng, Jiaxing Dong, Xiaoyu Li, Ying Xue, Jingbo Lan,* and Jingsong You*

Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of [Ch](#page-5-0)emistry, and State Ke[y L](#page-5-0)aboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, 29 Wangjiang Road, Chengdu 610064, P. R. China

S Supporting Information

unsymmetrical biazoles has been developed. The current catalytic system can effectively control the chemoselectivity for heterocoupling over homocoupling.

Transition-metal-catalyzed cross-coupling reactions of nucleophiles (organometallic reagents and hydrocarbons) with electrophiles (organohalides or surrogates) are powerful synthetic tools to construct carbon−carbon (C−C) bonds and have made significant progress over the past decades. $1/2$ However, from the viewpoint of synthetic simplicity and efficiency, atom economy, and sustainable chemistry, dir[ect](#page-5-0) dehydrogenative coupling through the cleavage of two C−H bonds would be one of the most ideal approaches for forming (hetero)aryl−(hetero)aryl bonds, which avoids prefunctionalization of both of substrates prior to the coupling reaction. 3 In recent years, a number of examples of dehydrogenative crosscoupling, including bet[we](#page-5-0)en arene and arene,⁴ between heteroarene and arene,⁵ and between heteroarene and heter[o](#page-5-0)arene,⁶ have been reported. Nevertheless, some formidable challenges still re[m](#page-5-0)ain to be overcome in this area, including a [co](#page-6-0)mpetition between cross-coupling and homocoupling. In general, the three tactics may be used to achieve such a chemoselectivity: (1) the use of two (hetero)arenes with distinctly different electronic characteristics; (2) the chelationdirected strategy; and (3) the utilization of an excessive amount of one of the coupling components (up to 40−100 equiv).

Imidazoles, oxazoles, and thiazoles are a class of privileged structural motifs in bioactive natural products, pharmaceuticals, and organic functional materials, and their functionalization has recently attracted extensive attention. Ofial and co-workers developed the palladium(II)-catalyzed dehydrogenative crosscoupling of benzazoles with azoles by using 1.5 equiv of one of coupling components.^{6d} Recently, we reported that the palladium(II) catalytic system could give a high level of selectivity of cross-cou[pli](#page-6-0)ng between two structurally similar azoles even when the ratio of two partners is $1:1.^{6b}$ While the

copper-catalytic systems effectively promote homocoupling of azoles,⁷ however, the copper-catalyzed cross-coupling reactions between two different azoles with high cross-coupling selecti[vi](#page-6-0)ty have not been reported yet. Herein, we describe for the first time a copper-catalytic dehydrogenative crosscoupling between two azoles with high chemoselectivity.

The dehydrogenative coupling reactions between two different azoles were carried out in a ratio of 1:1. The investigation started with the coupling of benzothiazole and 5 phenyloxazole in the presence of $Cu(OAc)₂$ by using Ag₂CO₃ as the oxidant, and the cross-coupling product 3a was obtained in 65% yield in xylene for 24 h at 140 °C (Table 1, entry 1). A negative effect was observed when an extra base such as Na₂CO₃ or *t*-BuOLi was employed (Table 1, en[tri](#page-1-0)es 2–4). In controlled experiments, none or a trace of cross-coupling product was observed in the absence of $Cu(OAc)₂$ $Cu(OAc)₂$ $Cu(OAc)₂$ or Ag₂CO₃ (Table 1, entries 5 and 6). Further improvement of the reaction efficiency was achieved when pyridine (1.0 equiv) was introd[uce](#page-1-0)d as an additive, and 3a was obtained in 76% isolated yield (Table 1, entry 7). When 40 mol % of pyridine was used, the yield of 3a decreased from 76% to 70% (Table 1, entry 8). Subsequentl[y,](#page-1-0) other copper salts (i.e., $Cu(OTf)_{2}$, $CuCl_{2}$, and $Cu(ac)₂$ $Cu(ac)₂$ $Cu(ac)₂$) were found to lead to lower catalytic efficiency (Table 1, entries 9−11). After screening a series of solvents, xylene turned out to be the best choice (Table 1, entries 7, 12− 15). In [a](#page-1-0)ddtion, shortening the reaction time and decreasing the reaction temperature could significantly [d](#page-1-0)iminish yields (Table 1, entries 17 and 18). Thus, the optimal reaction condition was obtained when 20 mol % of $Cu(OAc)₂$ was

Received: June 1, 2012 Published: August 17, 2012

a
Reactions were carried out using Cu salt (20 mol %), base (1.5 equiv), oxidant (1.5 equiv), additive (1.0 equiv), benzothiazole (0.25 mmol), 5phenyloxazole (0.25 mmol), and solvent (1.0 mL) at 140 °C for 24 h under oxygen atmosphere. ^BYield of isolated product. "Pyridine (40 mol %).
^HFor 12 h. ^eAt 120 °C. ^JUnder air atmosphere. ⁸Under N₂ atmosphere. dichloroethane, TEMPO = 2,2,6,6-tetramethyl-1-piperidinyloxy.

"Reactions were carried out using $Cu(OAc)_{2}$ (20 mol %), Ag₂CO₃ (1.5 equiv), pyridine (1.0 equiv), benzothiazole (0.5 mmol), and azole **2** (0.5 mmol) at 140 °C for 24 h under oxygen atmosphere. ^bYields of isolated pr benzothiazole (1a) and azole ², respectively. ^c For the detailed structure information of compounds, see Table S1 (Supporting Information).

^aReactions were carried out using Cu(OAc)₂ (20 mol %), Ag₂CO₃ (1.5 equiv), pyridine (1.0 equiv), azole 1 (0.5 mmol), and azole 2 (0.5 mmol) at
140 °C for 24 h under oxygen atmosphere. ^bYields of isolated product azole 2, respectively. For the detailed structure information of compounds, see Table S2 (Supporting Information). ^dOxazole 1 (0.5 mmol), and azole 2, respectively. For the detailed structure information of compounds, se imidazole 2 (0.75 mmol).

employed in combination with Ag_2CO_3 (1.5 equiv) and pyridine (1.0 equiv) in xylene at 140 °C for 24 h under oxygen atmosphere.

Subsequently, the dehydrogenative cross-couplings of benzothiazole 1a with various oxazoles were conducted under the optimized conditions (Table 2; for details, see Table S1, Supporting Information). It was found that benzothiazole could react with a relatively broad ran[ge](#page-1-0) of oxazoles to afford the [cross-coupling produc](#page-5-0)ts with the C2/C2′-selectivity in satisfactory yields. The substituents on a benzene ring of arylsubstituted oxazoles 2 had a negligible effect on the crosscoupling reactions (Table 2, 3a−f). Chloro and bromo substituents on the aromatic ring were tolerant in this catalytic system, which could be [su](#page-1-0)bjected to further synthetic transformations (Table 2, 3d,e). 5-(Pyridin-2-yl)oxazole could undergo the coupling reaction to provide 3g in 70% yield. In addition, the catalytic s[yst](#page-1-0)em was also suitable for other azoles (e.g., ethyl 4-methyloxazole-5-carboxylate, 2-phenyl-1,3,4-oxadiazole, and 1-methyl-1H-benzimidazole) (Table 2, $3h-j$).

The optimized conditions could be further extended to the reactions between two nonbenzofused azoles [\(T](#page-1-0)able 3; for details, see Table S2, Supporting Information). A variety of thiazole, oxazole, and imidazole derivatives were coupled to each other in accept[able yields. In compar](#page-5-0)ison with the reactions between benzothiazole with azoles, the homocoupling tendency between two nonbenzofused azoles was slightly

increased pr[obably](#page-5-0) [due](#page-5-0) [to](#page-5-0) [the](#page-5-0) [lea](#page-5-0)st difference in π -electronic characteristics. As illustrated in Table 3, 4,5-dimethylthiazole could be coupled efficiently at the 2-position with various oxazoles, affording the corresponding cross-coupling products in 62−73% yields (Table 3, 4a−e). Worthy of note was that some troublesome functional groups such as halide, ester, aldehyde, vinyl, and nitro could survive in the current catalytic system (Table 3, 4d−o). The C4 unsubstituted thiazole was amenable to the dehydrogenative coupling at the C2 position in synthetically useful yields (Table 3, 4k and 4l). Furthermore, the both C4 and C5 unsubstituted thiazole also selectively underwent the cross-coupling at the C2 position (Table 3, 4m; for the copy of HH−COSY spectrum of 4m, see the Supporting Information).

Although the mechanism remains not completely clear at this [stage, a plausible cata](#page-5-0)lytic cycle could involve (1) C−H cupration of one azole to generate the organocopper species (Azole 1)–CuL_n with a carbon–metal bond at the 2-position of azole, $7,8$ (2) subsequent formation of the critical mixed bisheteroaryl−Cu intermediate (Azole 1)−Cu−(azole 2), and (3) r[edu](#page-6-0)ctive elimination to afford the unsymmetrical 2,2′ bisazole. In order to gain mechanistic insights into the reaction, two control experiments were investigated. First, TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy, 1.0 equiv) as a radical scavenger was observed to display a negligible effect on the reaction of 1a and 2a, ruling out a radical pathway (Table 1,

entry 21). Next, kinetic isotope effects (KIE) were studied with regard to the $C-H/D$ bonds for both coupling partners.⁹ The parallel (independent) reactions were performed by the use of 2-deuterio-benzothiazole and 2-deuterio-5-phenyloxazole [u](#page-6-0)nder the optimized conditions (Scheme 1). The KIE values of 1.06

Scheme 1. Kinetic Isotope Effect Study

and 1.04 were observed for 2-deuteriobenzothiazole and 2 deuterio-5-phenyloxazole, respectively (Scheme 1, eq 1 and eq 2; for details, see the Supporting Information). These results clearly indicated that the C2−H bond breaking of azole was not involved in the rate-de[termining step in the pr](#page-5-0)esent reaction.

In summary, the $Cu(II)$ -catalyzed dehydrogenative couplings between two different azoles have been developed. The current copper-catalytic system is not only suitable for a relatively wide range of azoles (e.g., thiazoles, oxazoles, imidazoles, and oxadiazoles) but also compatible with the presence of functional groups (e.g., halide, nitro, cyano, ester, aldehyde, and vinyl groups). We expect that insights gained from our present study are helpful for the understanding of transitionmetal-catalyzed dehydrogenative cross-couplings between two hereoarenes.

EXPERIMENTAL SECTION

General Procedure for Dehydrogenative Cross-Couplings between Two Azoles. A flame-dried Schlenk test tube with a magnetic stirring bar was charged with copper species (20 mol %), Ag2CO3 (0.75 mmol), pyridine (0.5 mmol), azole 1 (0.5 mmol), azole 2 (0.5 mmol), and xylene (1 mL) under 1 atm of O_2 atmosphere. The resulting mixture was stirred for 10 min at room temperature and then heated at 140 °C for the indicated time. The mixture was cooled to room temperature, diluted with CH_2Cl_2 (20 mL), filtered through a Celite pad, and washed with CH₂Cl₂ (10−20 mL). The organic extracts were concentrated, and the resulting residue was purified by column chromatography on silica gel to provide the desired product and the homocoupling products .

2-(5-Phenyloxazol-2-yl)benzothiazole $(3a)$. The crude residue was purified by flash column chromatography on silica gel to afford 3a as a white solid (106 mg, 76%), 1aa (7 mg, 10%), and 2aa (12 mg, 17%) (petroleum/ethyl acetate = $15/1-8/1$ v/v). ¹H NMR (400 MHz, CDCl₃): δ = 7.38 (t, J = 7.2 Hz, 1H), 7.45–7.50 (m, 3H), 7.54–7.58 $(m, 2H)$, 7.82 (d, J = 7.6 Hz, 2H), 7.95 (d, J = 8.0 Hz, 1H), 8.20 (d, J $= 8.0$ Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 121.9$, 124.3, 124.4, 125.1, 126.7, 127.0, 127.1, 129.1, 129.5, 135.4, 153.6, 153.8, 154.5, 155.8 ppm. HRMS (ESI⁺): calcd for $C_{16}H_{11}N_2OS$ $[M + H]^+$ 279.0592, found 279.0594.

2,2'-Bibenzothiazole (1aa, Known Compound). ¹H NMR (400 MHz, CDCl₃): $\delta = 7.39 - 7.71$ (m, 4H), 7.92 (d, J = 7.6 Hz, 2H), 8.10−8.16 (m, 2H) ppm. ¹³C NMR (150 MHz, CDCl₃): δ = 122.2, 124.2, 126.8, 127.0, 127.7, 129.2, 136.0 ppm. HRMS (ESI⁺): calcd for $C_{14}H_9N_2S_2$ [M + H]⁺ 269.0207, found 269.0200.

5,5′-Diphenyl-2,2′-bioxazole (**2aa**, Known Compound). ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta = 7.38 \text{ (t, } J = 7.2 \text{ Hz, } 2\text{H}), 7.45 \text{ (t, } J = 7.6 \text{ Hz},$ 4H), 7.57 (s, 2H), 7.79 (d, J = 7.6 Hz, 4H) ppm. 13C NMR (100 MHz, CDCl₃): δ = 124.0, 125.0, 127.1, 129.2, 129.5, 153.2 ppm.

2-(5-(2-Methoxyphenyl)oxazol-2-yl)benzothiazole (3b). The crude residue was purified by flash column chromatography on silica gel to afford 3b as an off-white solid (116 mg, 75%), 1aa (9 mg, 13%), and 2bb (13 mg, 15%) (petroleum/ethyl acetate = $8/1 - 5/1$ v/v). ¹H NMR (400 MHz, CDCl₃): δ = 4.00 (s, 3H), 6.99 (d, J = 8.4 Hz, 1H), 7.07 (t, $J = 7.6$ Hz, 1H), 7.34 (t, $J = 7.8$ Hz, 1H), 7.45 (t, $J = 7.4$ Hz, 1H), 7.53 (t, $J = 7.6$ Hz, 1H), 7.77 (s, 1H), 7.94 (d, $J = 8.0$ Hz, 1H), 8.05 (d, J = 7.6 Hz, 1H), 8.20 (d, J = 8.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 55.6, 111.0, 116.3, 121.0, 121.9, 124.3, 126.5,$ 126.9, 127.0, 128.4, 130.2, 135.4, 150.2, 153.9, 154.7, 156.3 ppm. HRMS (ESI⁺): calcd for $C_{17}H_{13}N_2O_2S$ $[M + H]^+$ 309.0698, found 309.0706.

5,5′-Di(2-methoxyphenyl)-2,2′-bioxazole (2bb, Known Compound). Mp: 233–235 °C. ¹H NMR (400 MHz, CDCl₃): δ = 4.00 $(s, 6H)$, 6.99 (d, J = 8.4 Hz, 2H), 7.06 (t, J = 7.6 Hz, 2H), 7.33 (t, J = 7.6 Hz, 2H), 7.76 (s, 2H), 8.00 (d, $J = 7.6$ Hz, 2H) ppm. ¹³C NMR $(100 \text{ MHz}, \text{CDCl}_3)$: $\delta = 55.7, 111.0, 111.7, 116.5, 121.1, 122.4, 126.8,$ 130.1, 135.2, 156.2 ppm. HRMS (ESI⁺): calcd for $C_{20}H_{17}N_2O_4$ [M + H]⁺ 349.1188, found 349.1179.

2-(5-(4-Cyanophenyl)oxazol-2-yl)benzothiazole (3c). The crude residue was purified by flash column chromatography on silica gel to afford 3c as an off-white solid (114 mg, 75%) and 1aa (7 mg, 10%) (petroleum/ethyl acetate = $15/1-8/1$ v/v). ¹H NMR (400 MHz, CDCl₃): δ = 7.49 (t, J = 7.6 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 7.70 (s, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 7.6 Hz, 1H), 8.21 (d, J = 8.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 112.7, 118.4, 122.0, 124.6, 125.3, 126.8, 127.1, 127.3, 131.0, 133.0, 135.6, 151.5, 153.8, 153.8(4), 156.9 ppm. HRMS (ESI⁺): calcd for $C_{17}H_{10}N_3OS$ [M + H]⁺ 304.0545, found 304.0530.

2-(5-(4-Chlorophenyl)oxazol-2-yl)benzothiazole (3d). The crude residue was purified by flash column chromatography on silica gel to afford 3d as a white solid (108 mg, 69%), 1aa (7 mg, 10%), and 2dd (8 mg, 8%) (petroleum/ethyl acetate = $10/1-8/1$ v/v). ¹H NMR $(400 \text{ MHz}, \text{CDCl}_3): \delta = 7.42 \text{ (d, } J = 8.4 \text{ Hz}, 2H), 7.47 \text{ (t, } J = 7.6 \text{ Hz},$ 1H), 7.55−7.58 (m, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.95 (d, J = 8.0 Hz, 1H), 8.19 (d, J = 8.4 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 122.0, 124.5, 124.6, 125.6, 126.3, 126.8, 127.1, 129.5, 135.4, 152.6, 153.8, 154.3, 156.0 ppm. HRMS (ESI⁺): calcd for C₁₆H₁₀ClN₂OS [M + H]⁺ 313.0202, found 313.0208.

5,5′-Di(4-chlorophenyl)-2,2′-bioxazole (2dd). Mp: 233−²³⁵ °C. ¹ ¹H NMR (400 MHz, CDCl₃): δ = 7.44 (d, J = 8.4 Hz, 4H), 7.56 (s, 2H), 7.72 (d, J = 8.4 Hz, 4H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 124.4, 125.6, 126.2, 129.3, 129.6, 135.5 ppm. HRMS (ESI⁺): calcd for $C_{18}H_{10}Cl_2N_2NaO_2$ [M + Na]⁺ 379.0017, found 379.0047.

2-(5-(4-Bromophenyl)oxazol-2-yl)benzothiazole (3e, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 3e as a white solid (123 mg, 69%) and 1aa (9 mg, 13%) (petroleum/ethyl acetate = 10/1−8/1 v/ v). ¹H NMR (400 MHz, CDCl₃): δ = 7.46 (t, J = 7.6 Hz, 1H), 7.53– 7.57 (m, 3H), 7.59 (s, 1H), 7.66 (d, J = 8.4 Hz, 2H), 7.94 (d, J = 8.0 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 121.9, 123.6, 124.4, 124.6, 125.9, 126.4, 126.7, 127.0, 132.3, 135.4, 152.5, 153.7, 154.1, 155.9 ppm. HRMS (ESI+): calcd for $C_{16}H_{10}BrN_2OS$ $[M + H]^+$ 356.9697, found 356.9702.

2-(5-(4-Nitrophenyl)oxazol-2-yl)benzothiazole (3f). The crude residue was purified by flash column chromatography on silica gel to afford 3f as a yellow solid (115 mg, 71%) and 1aa (9 mg, 13%) (petroleum/ethyl acetate = $3/1-2/1$ v/v). ¹H NMR (400 MHz, CDCl₃): δ = 7.50 (t, J = 7.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.75 (s, 1H), 7.98 (d, J = 8.4 Hz, 3H), 8.22 (d, J = 8.0 Hz, 1H), 8.32 (d, J = 8.8 Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 122.0, 124.6, 124.7, 125.0, 125.5, 127.2, 127.3, 132.8, 135.6, 147.9, 151.2, 153.8, 157.2 ppm. HRMS (ESI⁺): calcd for $C_{16}H_{10}N_3O_3S$ [M + H]⁺ 324.0443, found 324.0423.

 $2-(5-(Pyridin-2-yl)oxazol-2-yl)benzothiazole$ (3g). The crude residue was purified by flash column chromatography on silica gel to afford 3g as a white solid (98 mg, 70%), 1aa (8 mg, 12%), and 2gg (13 mg, 18%) (petroleum/ethyl acetate = 4/1−2/1 v/v). ¹ H NMR (400 MHz, CDCl₃): δ = 7.28–7.29 (m, 1H), 7.48 (t, J = 7.2 Hz, 1H), 7.55 (t, J = 7.6 Hz, 1H), 7.79 (t, J = 7.6 Hz, 1H), 7.94−7.98 (m, 3H), 8.20 $(d, J = 8.0 \text{ Hz}, 1\text{H})$, 8.66 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 120.2, 122.0, 123.8, 124.5, 126.9, 127.1, 127.6, 135.5, 137.1, 146.6, 150.2, 152.8, 153.8, 154.3, 156.4 ppm. HRMS (ESI⁺): calcd for $C_{15}H_{10}N_3OS$ [M + H]⁺ 280.0545, found 280.0542.

5,5′-Di(pyridin-2-yl)-2,2′-bioxazole (2gg, Known Compound). Mp: 233–235 °C. ¹H NMR (400 MHz, CDCl₃): δ = 7.29 (t, J = 6.0 Hz, 2H), 7.81 (t, J = 7.6 Hz, 2H), 7.89 (d, J = 8.0 Hz, 2H), 7.95 (s, 2H), 8.68 (s, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 120.0, 123.8, 127.4, 137.2, 146.6, 150.2, 150.9, 152.7 ppm. HRMS (ESI⁺): calcd for $C_{16}H_{11}N_4O_2$ [M + H]⁺ 291.0882, found 291.0875.

Ethyl 2-(Benzothiazol-2-yl)-4-methyloxazole-5-carboxylate (3h). The crude residue was purified by flash column chromatography on silica gel to afford 3h as an off-white solid (92 mg, 64%) and 1aa (7 mg, 10%) (petroleum/ethyl acetate = 15/1−8/1 v/v). ¹ H NMR (400 MHz, CDCl₃): δ = 1.41 (t, J = 7.0 Hz, 3H), 2.60 (s, 3H), 4.41 (q, J = 7.0 Hz, 2H), 7.49 (t, J = 7.4 Hz, 1H), 7.55 (t, J = 7.4 Hz, 1H), 7.96 (d, $J = 7.6$ Hz, 1H), 8.21 (d, $J = 8.0$ Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 13.5, 14.6, 61.6, 122.0, 125.0, 127.2, 127.3, 135.8, 139.0, 147.6, 153.3, 153.8, 156.2, 158.4 ppm. HRMS (ESI⁺): calcd for $C_{14}H_{13}N_2O_3S$ [M + H]⁺ 289.0647, found 289.0650.

Diethyl 4,4′-Dimethyl-2,2′-bioxazole-5,5′-dicarboxylate (2hh, Known Compound). Mp: 170−172 °C. ¹ H NMR (400 MHz, CDCl₃): $\delta = 1.38$ (t, J = 6.8 Hz, 6H), 2.56 (s, 6H), 4.38 (q, J = 6.8) Hz, 4H) ppm. 13 C NMR (100 MHz, CDCl₃): δ = 13.5, 14.4, 61.8, 139.3, 147.5, 150.1, 158.1 ppm. HRMS (ESI⁺): calcd for $C_{14}H_{16}N_2O_6$ $[M + H]^+$ 309.1087, found 309.1091.

2-(5-Phenyl-1,3,4-oxadiazol-2-yl)benzothiazole (3i, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 3i as an off-white solid (109 mg, 78%) and 1aa (8 mg, 12%) (petroleum/ethyl acetate = 15/1−8/1 v/v). ¹H NMR (400 MHz, CDCl₃): δ = 7.54–7.58 (m, 5H), 7.99 (d, J $= 7.6$ Hz, 1H), 8.23 (d, J = 7.6 Hz, 3H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 122.1, 123.1, 124.8, 127.4, 127.5, 127.7, 129.3, 132.6, 135.6, 150.9, 153.4, 160.3, 166.0 ppm. HRMS (ESI⁺): calcd for $C_{15}H_{10}N_3OS$ [M + H]⁺ 280.0545, found 280.0549.

2-(Benzothiazol-2-yl)-1-methyl-1H-benzoimidazole (3j, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 3j as an off-white solid (89 mg, 67%), 1aa (9 mg, 13%), and 2jj (12 mg, 18%) (petroleum/ethyl acetate = $5/1-3/1$ v/v). ¹H NMR (400 MHz, CDCl₃): δ = 4.42 (s, 3H), 7.33–7.41 (m, 2H), 7.44–7.48 (m, 2H), 7.51 (t, J = 7.6 Hz, 1H), 7.87 (d, $J = 7.6$ Hz, 1H), 7.97 (d, $J = 8.0$ Hz, 1H), 8.10 (d, $J = 8.0$ Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 32.2, 110.2, 120.7, 121.9, 123.4, 124.0, 124.6, 126.3, 126.6, 135.5, 137.4, 142.9, 145.3, 154.2, 156.0 ppm. HRMS (ESI⁺): calcd for $C_{15}H_{12}N_3S$ [M + H]⁺ 266.0752, found 266.0761.

1,1′-Dimethyl-2,2′-bibenzoimidazole (2jj, Known Compound). Mp: 170−172 °C. ¹H NMR (400 MHz, CDCl₃): δ = 4.34 (s, 6H), 7.35−7.43 (m, 4H), 7.49 (d, J = 7.6 Hz, 2H), 7.88 (d, J = 7.6 Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 32.6, 110.2, 120.5, 123.0, 124.1, 136.4, 142.7, 143.4 ppm. HRMS (ESI⁺): calcd for C₁₆H₁₅N₄ [M $+ H$ ⁺ 263.1297, found 263.1287.

2-(4,5-Dimethylthiazol-2-yl)-5-phenyloxazole (4a, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4a as an off-white solid (83 mg, 65%), 1bb (7 mg, 13%), and 2aa (14 mg, 19%) (petroleum/ dichloromethane/ethyl acetate = $15/2/1-8/2/1$ v/v). Mp: 103-105 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.45 (s, 6H), 7.34 (t, J = 7.2 Hz, 1H), 7.42−7.45 (m, 3H), 7.76 (d, J = 7.6 Hz, 2H) ppm. 13C NMR $(100 \text{ MHz}, \text{CDCl}_3)$: $\delta = 11.6, 14.9, 123.6, 124.7, 124.9, 127.3, 128.9,$ 130.0, 149.8, 150.7, 152.1, 155.9 ppm. HRMS (ESI⁺): calcd for $C_{14}H_{13}N_2OS$ [M + H]⁺ 257.0749, found 257.0745.

4,4′,5,5′-Tetramethyl-2,2′-bithiazole (1bb, Known Compound). ¹H NMR (400 MHz, CDCl₃): δ = 2.35 (s, 6H), 2.37 (s, 6H) ppm.¹³C NMR (100 MHz, CDCl₃): δ = 11.7, 14.9, 128.3, 149.6, 157.2 ppm.

2-(4,5-Dimethylthiazol-2-yl)-5-(pyridin-2-yl)oxazole (4b, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4b as a yellow solid (80 mg, 62%), 1bb as a white solid $(9 \text{ mg}, 16\%)$, and $2gg$ as a white solid (13 mg) mg, 18%) (petroleum/ethyl acetate = 5/1−2/1 v/v). Mp: 124−126 $^{\circ}$ C. ¹H NMR (400 MHz, CDCl₃): δ = 2.44 (s, 6H), 7.22–7.25 (m, 1H), 7.74 (t, J = 7.6 Hz, 1H), 7.82 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 8.61−8.62 (m, 1H) ppm. 13C NMR (100 MHz, CDCl3): δ = 10.6, 13.9, 118.7, 122.2, 126.0, 135.9, 143.6, 145.8, 148.6, 148.9, 150.0,

150.5, 155.6 ppm. HRMS (ESI⁺): calcd for $C_{13}H_{12}N_3OS$ $[M + H]^+$ 258.0701, found 258.0696.
2-(4,5-Dimethylthiazol-2-yl)-5-(2-methoxyphenyl)oxazole (4c,

Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4c as a pale yellow solid (100 mg, 70%), and 1bb as a white solid (12 mg, 21%) (petroleum/ethyl acetate = 10/1−5/1 v/v). Mp: 164−165 °C. ¹ H NMR (400 MHz, CDCl₃): δ = 2.43 (s, 6H), 3.96 (s, 3H), 6.96 (d, J = 8.4 Hz, 1H), 7.02 $(t, J = 7.6 \text{ Hz}, 1H)$, 7.29 $(t, J = 7.6 \text{ Hz}, 1H)$, 7.65 $(s, 1H)$, 7.96 $(d, J =$ 7.6 Hz, 1H) ppm. ¹³C NMR (150 MHz, CDCl₃): δ = 11.6, 15.0, 55.6, 110.8, 116.6, 120.9, 126.6, 127.8, 129.6, 129.8, 148.8, 150.1, 150.7, 154.9, 156.0 ppm. HRMS (ESI⁺): calcd for $C_{15}H_{15}N_2O_2S$ [M + H]⁺

287.0854, found 287.0851.
5-(4-Bromophenyl)-2-(4,5-dimethylthiazol-2-yl)oxazole (4d, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4d as a yellow solid (122 mg, 73%), and 1bb as a white solid (13 mg, 23%) (petroleum/ dichloromethane/ethyl acetate = $10/2/1-6/2/1$ v/v). Mp: 147-149 °C. ¹H NMR (400 MHz, CDCl₃): δ = 2.44 (s, 6H), 7.44 (s, 1H), 7.54 (d, $J = 8.0$ Hz, 2H), 7.61 (d, $J = 8.4$ Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 11.7, 15.0, 123.0, 124.2, 126.2, 126.3, 130.4, 132.2, 149.7, 150.9, 151.2, 156.2 ppm. HRMS (ESI+): calcd for $C_{14}H_{12}BrN_2OS$ $[M + H]^+$ 334.9854, found 334.9852.

Ethyl 2-(4,5-Dimethylthiazol-2-yl)-4-methyloxazole-5-carboxylate (4e, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4e as a white solid (97 mg, 73%), 1bb as a white solid (10 mg, 18%), and 2hh as a white solid (6 mg, 8%) (petroleum/ethyl acetate =10/1−5/1 v/v). Mp: 95− 97 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.37 (t, J = 7.2 Hz, 3H), 2.42 $(s, 3H)$, 2.44 $(s, 3H)$, 2.53 $(s, 3H)$, 4.36 $(q, J = 7.2 \text{ Hz}, 2H)$ ppm. ¹³C NMR (150 MHz, CDCl₃): $\delta = 11.8, 13.5, 14.4, 14.9, 61.4, 131.9,$ 137.8, 147.4, 148.4, 151.7, 156.5, 158.6 ppm. HRMS (ESI⁺): calcd for $C_{12}H_{15}N_2O_3S$ [M + H]⁺ 267.0803, found 267.0805.

Ethyl 4-Methyl-2-(5-phenyloxazol-2-yl)thiazole-5-carboxylate (4f). The crude residue was purified by flash column chromatography on silica gel to afford 4f as a white solid (96 mg, 61%), 1cc (20 mg, 23%), and 2aa (9 mg, 12%) (petroleum/ethyl acetate =15/1−8/1 v/ v). Mp: 123−125 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.36 (t, J = 8.0 Hz, 3H), 2.84 (s, 3H), 4.35 (q, J = 7.2 Hz, 2H), 7.37 (t, J = 7.0 Hz, 1H), 7.43 (t, J = 7.4 Hz, 2H), 7.52 (s, 1H), 7.77 (d, J = 7.6 Hz, 2H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.4, 17.6, 61.8, 124.3, 125.0, 127.0, 129.2, 129.6, 130.2, 153.4, 155.2, 155.7, 161.6, 161.9 ppm. HRMS (ESI⁺): calcd for $C_{16}H_{15}N_2O_3S$ $[M + H]^+$ 315.0803, found

315.0806.
Diethyl 4,4'-Dimethyl-2,2'-bithiazole-5,5'-dicarboxylate (1cc, Diethyl 4,4′-Dimethyl-2,2′-bithiazole-5,5′-dicarboxylate (1cc, Known Compound). Mp: 184−¹⁸⁶ °C. ¹ H NMR (400 MHz, CDCl₃): δ = 1.36 (t, J = 7.2 Hz, 6H), 2.77 (s, 6H), 4.33 (q, J = 7.2 Hz, 4H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.4, 17.6, 61.7, 124.7, 161.4, 162.0 ppm. HRMS (ESI⁺): calcd for $C_{14}H_{17}N_2O_4S_2$ [M + H]⁺ 341.0630, found 341.0624.

Ethyl 2-(5-(Ethoxycarbonyl)-4-methylthiazol-2-yl)-4-methyloxazole-5-carboxylate (4g, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4g as a white solid (102 mg, 63%), and 1cc as a pale yellow solid (18 mg, 21%) (petroleum/ethyl acetate = 10/1–7/1 v/v). Mp: 122–124 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.34–1.40 (m, 6H), 2.53 (s, 3H), 2.79 (s, 3H), 4.32–4.42 (m, 4H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 13.4, 14.3, 14.4, 17.5, 61.6, 61.9, 125.5, 138.6, 147.5, 154.3, 155.5, 158.2, 161.5, 161.8 ppm. HRMS (ESI⁺): calcd for C₁₄H₁₇N₂O₅S [M + H]⁺ 325.0858, found 325.0851.

Ethyl 2-(5-Formyl-4-methylthiazol-2-yl)-4-methyloxazole-5-carboxylate (4h, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4h as an offwhite solid (98 mg, 70%) (petroleum/ethyl acetate = 15/1−8/1 v/v). Mp: 123–125 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.40 (t, J = 7.2 Hz, 3H), 2.57 (s, 3H), 2.85 (s, 3H), 4.40 (q, J = 7.2 Hz, 2H), 10.16 (s, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 13.5, 14.4, 16.5, 61.8, 135.4, 139.1, 147.8, 155.3, 157.8, 158.2, 162.7, 182.2 ppm. HRMS (ESI⁺): calcd for C₁₂H₁₃N₂O₄S [M + H]⁺ 281.0596, found 281.0599. 4-Methyl-2-(5-phenyloxazol-2-yl)thiazole-5-carbaldehyde (4i, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4i as a yellow solid (88 mg, 65%) and 2aa as a white solid (14 mg, 19%) (petroleum/ethyl acetate = 10/1–5/1 v/v). Mp: 152–154 °C. ¹H NMR (400 MHz, CDCl₃): δ $= 2.85$ (s, 3H), 7.39 (t, J = 7.2 Hz, 1H), 7.45 (t, J = 7.2 Hz, 2H), 7.57 $(s, 1H)$, 7.78 (d, J = 7.2 Hz, 2H), 10.15 (s, 1H) ppm. ¹³C NMR (150 MHz, CDCl₃): $\delta = 16.5, 124.8, 125.1, 126.8, 129.2, 129.8, 134.3,$ 153.9, 155.0, 159.0, 162.6, 182.3 ppm. HRMS (ESI⁺): calcd for $C_{14}H_{11}N_2O_2S$ [M + H]⁺ 271.0541, found 271.0544.

Ethyl 2-(5-(2-Methoxyethyl)-4-methylthiazol-2-yl)-4-methyloxazole-5-carboxylate (4j, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4j as an off-white solid (102 mg, 66%) (petroleum/ethyl acetate = 7/1−4/1 v/ v). Mp: 64–66 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.37 (t, J = 7.2 Hz, 3H), 2.45 (s, 3H), 2.53 (s, 3H), 3.03 (t, J = 6.2 Hz, 2H), 3.36 (s, 3H), 3.57 (t, J = 6.0 Hz, 2H), 4.36 (q, J = 7.2 Hz, 2H) ppm. ¹³C NMR $(150 \text{ MHz}, \text{CDCl}_3): \delta = 13.5, 14.4, 15.3, 27.5, 58.9, 61.3, 71.9, 134.0,$ 137.8, 147.4, 149.7, 151.7, 156.6, 158.6 ppm. HRMS (ESI⁺): calcd for $C_{14}H_{19}N_2O_4S$ [M + H]⁺ 311.1066, found 311.1065.

Ethyl 2-(5-(Ethoxycarbonyl)thiazol-2-yl)-4-methyloxazole-5-carboxylate (4k, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4k as a white solid $(98 \text{ mg}, 63\%)$, 1ff as a pale yellow solid $(12 \text{ mg}, 15\%)$, and 2hh as a white solid (15 mg, 19%) (petroleum/ethyl acetate = 10/1−7/1 v/v). Mp: 116−118 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.39−1.42 (m, 6H), 2.57 (s, 3H), 4.38−4.44 (m, 4H), 8.52 (s, 1H) ppm. 13C NMR (100 MHz, CDCl₃): δ = 13.4, 14.3, 14.4, 61.6, 62.3, 132.8, 138.8, 147.5, 149.7, 155.3, 157.6, 158.2, 160.6 ppm. HRMS (ESI⁺): calcd for $C_{13}H_{15}N_2O_5S$ $[M + H]^+$ 311.0702, found 311.0703.

Diethyl 2,2′-Bithiazole-5,5′-dicarboxylate (1ff, Known Compound). Mp: 183–185 °C. ¹H NMR (400 MHz, CDCl₃): $\delta = 1.39$ $(t, J = 7.2 \text{ Hz}, 6\text{H})$, 4.38 $(q, J = 7.2 \text{ Hz}, 4\text{H})$, 8.45 $(s, 2\text{H})$ ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 14.4, 62.2, 132.2, 149.4, 161.0 165.1 ppm. HRMS (ESI⁺): calcd for $C_{12}H_{13}N_2O_4S_2$ [M + H]⁺ 313.0317, found 313.0317.

Ethyl 2-(5-Phenyloxazol-2-yl)thiazole-5-carboxylate (4l, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4l as a yellow solid (97 mg, 65%), 1ff as a pale yellow solid (10 mg, 13%), and 2aa as a white solid (8 mg, 11%) (petroleum/ethyl acetate = 10/1−7/1 v/v). Mp: 104− 107 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.39 (t, J = 7.2 Hz, 3H), 4.39 (q, J = 7.2 Hz, 2H), 7.37 (t, J = 7.2 Hz, 1H), 7.44 (t, J = 7.2 Hz, 2H), 7.53 (s, 1H), 7.77 (d, J = 7.6 Hz, 2H), 8.51 (s, 1H) ppm. ¹³C NMR (150 MHz, CDCl₃): δ = 14.4, 62.2, 124.4, 125.0, 126.9, 129.2, 129.6, 131.5, 149.5, 153.5, 155.1, 158.9, 161.0 ppm. HRMS (ESI⁺): calcd for $C_{15}H_{12}N_2O_3S$ $[M + H]^+$ 301.0647, found 301.0652.

Ethyl 4-Methyl-2-(thiazol-2-yl)oxazole-5-carboxylate (4m, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4m as a pale yellow solid (71 mg, 60%) (petroleum/ethyl acetate = 10/1−5/1 v/v). Mp: 106−108 $^{\circ}C.$ ¹H NMR (400 MHz, CDCl₃): δ = 1.39 (t, J = 7.2 Hz, 3H), 2.56 (s, 3H), 4.38 (q, $J = 7.2$ Hz, 2H), 7.57 (d, $J = 2.4$ Hz, 1H), 8.03 (d, $J = 2.0$ Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): δ = 13.4, 14.4, 61.5, 123.0, 138.3, 145.3, 147.4, 153.8, 156.2, 158.5 ppm. HRMS (ESI⁺): calcd for $C_{10}H_{11}N_2O_3S$ $[M + H]^+$ 239.0490, found 239.0495.

Ethyl 4-Methyl-2-(1-vinyl-1H-imidazol-2-yl)oxazole-5-carboxylate (4n, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4n as a white solid (72 mg, 58%) (petroleum/ethyl acetate = $4/1−2/1$ v/v). Mp: 151– 153 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.36 (t, J = 7.2 Hz, 3H), 2.54 (s, 3H), 4.36 (q, J = 7.2 Hz, 2H), 5.07 (d, J = 8.8 Hz, 1H), 5.36 $(d, J = 15.6 \text{ Hz}, 1\text{H}), 7.26 \text{ (s, 1H)}, 7.45 \text{ (s, 1H)}, 8.14 \text{ (dd, } J = 15.6 \text{ Hz},$ $J = 8.8$ Hz, 1H) ppm. ¹³C NMR (100 MHz, CDCl₃): $\delta = 13.4$, 14.4, 61.3, 104.1, 118.8, 130.5, 131.4, 134.2, 137.3, 146.7, 153.4, 158.6 ppm. HRMS (ESI⁺): calcd for $C_{12}H_{14}N_3O_3$ $[M + H]^+$ 248.1035, found 248.1034.

Ethyl 4-Methyl-2-(1-methyl-4-nitro-1H-imidazol-2-yl)oxazole-5 carboxylate (40, Known Compound). The crude residue was purified by flash column chromatography on silica gel to afford 4o as a white solid (73 mg, 52%) (petroleum/ethyl acetate = $2/1-1/1$ v/v). Mp: 155−157 °C. ¹H NMR (400 MHz, CDCl₃): δ = 1.36 (t, J = 7.2 Hz,

3H), 2.53 (s, 3H), 4.22 (s, 3H), 4.35 (q, J = 7.2 Hz, 2H), 7.92 (s, 1H) ppm. 13 C NMR (100 MHz, CDCl3): δ = 13.4, 14.4, 37.2, 61.6, 124.0, 133.8, 138.2, 146.7, 151.9, 158.3 ppm. HRMS (ESI⁺): calcd for $C_{11}H_{13}N_4O_5$ [M + H]⁺ 281.0886, found 281.0890.

■ ASSOCIATED CONTENT

6 Supporting Information

Data and copies of NMR for compounds and detailed heterocouplings and homocouplings. This material is available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: (J.Y.) jsyou@scu.edu.cn; (J.L.) jingbolan@scu.edu.cn. Notes

The authors de[clare no competin](mailto:jsyou@scu.edu.cn)g finan[cial interest.](mailto:jingbolan@scu.edu.cn)

■ ACKNOWLEDGMENTS

This work was supported by grants from the National NSF of China (Nos. 21172155, 20972102, 21025205, 21021001, and J1103315/J0104) and the National Basic Research Program of China (973 Program, 2011CB8086600). We thank the Centre of Testing & Analysis, Sichuan University, for NMR measurements.

■ REFERENCES

(1) Zhao, D.; You, J.; Hu, C. Chem.-Eur. J. 2011, 17, 5466.

(2) For recent selected reviews for direct C−H functionalization, see: (a) Ackermann, L. Chem. Rev. 2011, 111, 1315. (b) Wencel-Delord, J.; Dröge, T.; Liu, F.; Glorius, F. Chem. Soc. Rev. 2011, 40, 4740. (c) Chiusoli, G. P.; Catellani, M.; Costa, M.; Motti, E.; Della Cá, N.; Maestri, G. Coor. Chem. Rev. 2010, 254, 456. (d) Colby, D. A.; Bergman, R. G.; Ellman, J. A. Chem. Rev. 2010, 110, 624. (e) McGlacken, G. P.; Bateman, L. M. Chem. Soc. Rev. 2009, 38, 2447. (f) Ackermann, L; Vicente, R.; Kapdi, A. R. Angew. Chem., Int. Ed. 2009, 48, 9792. (g) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem., Int. Ed. 2009, 48, 5094. (h) Lewis, J. C.; Bergman, R. G.; Ellman, J. A. Acc. Chem. Res. 2008, 41, 1013. (i) Seregin, I. V.; Gevorgyan, V. Chem. Soc. Rev. 2007, 36, 1173. (j) Alberico, D.; Scott, M. E.; Lautens, M. Chem. Rev. 2007, 107, 174.

(3) For recent reviews, see: (a) Liu, C.; Zhang, H.; Shi, W.; Lei, A. Chem. Rev. 2011, 111, 1780. (b) Yeung, C. S.; Dong, V. M. Chem. Rev. 2011, 111, 1215. (c) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. Chem. Soc. Rev. 2011, 40, 5068. (d) Wendlandt, A. E.; Suess, A. M.; Stahl, S. S. Angew. Chem., Int. Ed. 2011, 50, 11062. (e) Bugaut, X.; Glorius, F. Angew. Chem., Int. Ed. 2011, 50, 7479. (f) Han, W.; Ofial, A. R. Synlett 2011, 14, 1951.

(4) For oxidative couplings between two arenes, see: (a) Faggi, E.; Sebastián, R. M.; Pleixats, R.; Vallribera, A.; Shafir, A.; Rodríguez-Gimeno, A.; de Arellano, C. R. J. Am. Chem. Soc. 2010, 132, 17980. (b) Wei, Y.; Su, W. J. Am. Chem. Soc. 2010, 132, 16377. (c) Zhao, X.; Yeung, C. S.; Dong, V. M. J. Am. Chem. Soc. 2010, 132, 5837. (d) Hull, K. L.; Sanford, M. S. J. Am. Chem. Soc. 2009, 131, 9651. (e) Dohi, T.; Ito, M.; Morimoto, K.; Iwata, M.; Kita, Y. Angew. Chem., Int. Ed. 2008, 47, 1301. (f) Li, B.-J; Tian, S.-L.; Fang, Z.; Shi, Z.-J. Angew. Chem., Int. Ed. 2008, 47, 1115. (g) Brasche, G.; García-Fortanet, J.; Buchwald, S. L. Org. Lett. 2008, 10, 2207. (h) Xia, J.-B.; You, S.-L. Organometallics 2007, 26, 4869. (i) Li, R.; Jiang, L.; Lu, W. Organometallics 2006, 25, 5973.

(5) For oxidative couplings between heteroarene and arene, see: (a) Pintori, D. G.; Greaney, M. F. J. Am. Chem. Soc. 2011, 133, 1209. (b) Kitahara, M.; Umeda, N.; Hirano, K.; Satoh, T.; Miura, M. J. Am. Chem. Soc. 2011, 133, 2160. (c) Malakar, C. C.; Schmidt, D.; Conrad, J.; Beifuss, U. Org. Lett. 2011, 13, 1378. (d) Potavathri, S.; Pereira, K. C.; Gorelsky, S. I.; Pike, A.; LeBris, A. P.; DeBoef, B. J. Am. Chem. Soc. 2010, 132, 14676. (e) He, C.-Y.; Fan, S.; Zhang, X. J. Am. Chem. Soc.

The Journal of Organic Chemistry Note

2010, 132, 12850. (f) Cho, S. H.; Hwang, S. J.; Chang, S. J. Am. Chem. Soc. 2008, 130, 9254. (g) Dwight, T. A.; Rue, N. R.; Charyk, D.; Josselyn, R.; DeBoef, B. Org. Lett. 2007, 9, 3137. (h) Stuart, D. R.; Fagnou, K. Science 2007, 316, 1172.

(6) For dehydrogenative couplings between two heteroarenes, see: (a) Nishino, M.; Hirano, K.; Satoh, T.; Miura, M. Angew. Chem., Int. Ed. 2012, 51, 6993. (b) Dong, J.; Huang, Y.; Qin, X.; Cheng, Y.; Hao, J.; Wan, D.; Li, W.; Liu, X.; You, J. Chem.-Eur. J. 2012, 18, 6158. (c) Wang, Z.; Li, K.; Zhao, D.; Lan, J.; You, J. Angew. Chem., Int. Ed. 2011, 50, 5365. (d) Han, W.; Mayer, P.; Ofial, A. R. Angew. Chem., Int. Ed. 2011, 50, 2178. (e) Gong, X.; Song, G.; Zhang, H.; Li, X. Org. Lett. 2011, 13, 1766. (f) Yamaguchi, A. D.; Mandal, D.; Yamaguchi, J.; Itami, K. Chem. Lett. 2011, 40, 555. (g) Do, H.-Q.; Daugulis, O. J. Am. Chem. Soc. 2011, 133, 13577. (h) Xi, P.; Yang, F.; Qin, S; Zhao, D.; Lan, J.; Gao, G.; Hu, C.; You, J. J. Am. Chem. Soc. 2010, 132, 1822.

(7) For copper-promoted homocoupling of azoles, see: (a) Zhu, M.; Fujita, K.; Yamaguchi, R. Chem. Commun. 2011, 47, 12876. (b) Li, Y.; Jin, J.; Qian, W.; Bao, W. Org. Biomol. Chem. 2010, 8, 326. (c) Monguchi, D.; Yamamura, A.; Fujiwara, T.; Somete, T.; Mori, A. Tetrahedron Lett. 2010, 51, 850.

(8) (a) Dudnik, A. S.; Gevorgyan, V. Angew. Chem., Int. Ed. 2010, 49, 2096. (b) Do, H.-Q.; Daugulis, O. J. Am. Chem. Soc. 2008, 130, 1128. (c) Ackermann, L.; Potukuchi, H. K.; Landsberg, D.; Vicente, R. Org. Lett. 2008, 10, 3081.

(9) (a) Simmons, E. M.; Hartwig, J. F Angew. Chem., Int. Ed. 2012, 51, 3066. (b) Kim, S. H.; Yoon, J.; Chang, S. Org. Lett. 2011, 13, 1474.